Literature DB >> 33704937

Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.

Eric J Duncavage1, Molly C Schroeder1, Michele O'Laughlin1, Roxanne Wilson1, Sandra MacMillan1, Andrew Bohannon1, Scott Kruchowski1, John Garza1, Feiyu Du1, Andrew E O Hughes1, Josh Robinson1, Emma Hughes1, Sharon E Heath1, Jack D Baty1, Julie Neidich1, Matthew J Christopher1, Meagan A Jacoby1, Geoffrey L Uy1, Robert S Fulton1, Christopher A Miller1, Jacqueline E Payton1, Daniel C Link1, Matthew J Walter1, Peter Westervelt1, John F DiPersio1, Timothy J Ley1, David H Spencer1.   

Abstract

BACKGROUND: Genomic analysis is essential for risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential replacement for conventional cytogenetic and sequencing approaches, but its accuracy, feasibility, and clinical utility have not been demonstrated.
METHODS: We used a streamlined whole-genome sequencing approach to obtain genomic profiles for 263 patients with myeloid cancers, including 235 patients who had undergone successful cytogenetic analysis. We adapted sample preparation, sequencing, and analysis to detect mutations for risk stratification using existing European Leukemia Network (ELN) guidelines and to minimize turnaround time. We analyzed the performance of whole-genome sequencing by comparing our results with findings from cytogenetic analysis and targeted sequencing.
RESULTS: Whole-genome sequencing detected all 40 recurrent translocations and 91 copy-number alterations that had been identified by cytogenetic analysis. In addition, we identified new clinically reportable genomic events in 40 of 235 patients (17.0%). Prospective sequencing of samples obtained from 117 consecutive patients was performed in a median of 5 days and provided new genetic information in 29 patients (24.8%), which changed the risk category for 19 patients (16.2%). Standard AML risk groups, as defined by sequencing results instead of cytogenetic analysis, correlated with clinical outcomes. Whole-genome sequencing was also used to stratify patients who had inconclusive results by cytogenetic analysis into risk groups in which clinical outcomes were measurably different.
CONCLUSIONS: In our study, we found that whole-genome sequencing provided rapid and accurate genomic profiling in patients with AML or MDS. Such sequencing also provided a greater diagnostic yield than conventional cytogenetic analysis and more efficient risk stratification on the basis of standard risk categories. (Funded by the Siteman Cancer Research Fund and others.).
Copyright © 2021 Massachusetts Medical Society.

Entities:  

Mesh:

Year:  2021        PMID: 33704937      PMCID: PMC8130455          DOI: 10.1056/NEJMoa2024534

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

Review 2.  Genome Sequencing during a Patient's Journey through Cancer.

Authors:  Jyoti Nangalia; Peter J Campbell
Journal:  N Engl J Med       Date:  2019-11-28       Impact factor: 91.245

3.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

6.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

7.  Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

Authors:  Eric J Duncavage; Meagan A Jacoby; Gue Su Chang; Christopher A Miller; Natasha Edwin; Jin Shao; Kevin Elliott; Joshua Robinson; Haley Abel; Robert S Fulton; Catrina C Fronick; Michelle O'Laughlin; Sharon E Heath; Kimberly Brendel; Raya Saba; Lukas D Wartman; Matthew J Christopher; Iskra Pusic; John S Welch; Geoffrey L Uy; Daniel C Link; John F DiPersio; Peter Westervelt; Timothy J Ley; Kathryn Trinkaus; Timothy A Graubert; Matthew J Walter
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

8.  Atlas of genetics and cytogenetics in oncology and haematology in 2013.

Authors:  Jean-Loup Huret; Mohammad Ahmad; Mélanie Arsaban; Alain Bernheim; Jérémy Cigna; François Desangles; Jean-Christophe Guignard; Marie-Christine Jacquemot-Perbal; Maureen Labarussias; Vanessa Leberre; Anne Malo; Catherine Morel-Pair; Hossein Mossafa; Jean-Claude Potier; Guillaume Texier; Franck Viguié; Sylvie Yau Chun Wan-Senon; Alain Zasadzinski; Philippe Dessen
Journal:  Nucleic Acids Res       Date:  2012-11-17       Impact factor: 16.971

9.  Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome.

Authors:  Michael Rusch; Joy Nakitandwe; Sheila Shurtleff; Scott Newman; Zhaojie Zhang; Michael N Edmonson; Matthew Parker; Yuannian Jiao; Xiaotu Ma; Yanling Liu; Jiali Gu; Michael F Walsh; Jared Becksfort; Andrew Thrasher; Yongjin Li; James McMurry; Erin Hedlund; Aman Patel; John Easton; Donald Yergeau; Bhavin Vadodaria; Ruth G Tatevossian; Susana Raimondi; Dale Hedges; Xiang Chen; Kohei Hagiwara; Rose McGee; Giles W Robinson; Jeffery M Klco; Tanja A Gruber; David W Ellison; James R Downing; Jinghui Zhang
Journal:  Nat Commun       Date:  2018-09-27       Impact factor: 14.919

10.  DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.

Authors:  Timothy J Ley; Elaine R Mardis; Li Ding; Bob Fulton; Michael D McLellan; Ken Chen; David Dooling; Brian H Dunford-Shore; Sean McGrath; Matthew Hickenbotham; Lisa Cook; Rachel Abbott; David E Larson; Dan C Koboldt; Craig Pohl; Scott Smith; Amy Hawkins; Scott Abbott; Devin Locke; Ladeana W Hillier; Tracie Miner; Lucinda Fulton; Vincent Magrini; Todd Wylie; Jarret Glasscock; Joshua Conyers; Nathan Sander; Xiaoqi Shi; John R Osborne; Patrick Minx; David Gordon; Asif Chinwalla; Yu Zhao; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark Watson; Jack Baty; Jennifer Ivanovich; Sharon Heath; William D Shannon; Rakesh Nagarajan; Matthew J Walter; Daniel C Link; Timothy A Graubert; John F DiPersio; Richard K Wilson
Journal:  Nature       Date:  2008-11-06       Impact factor: 49.962

View more
  32 in total

1.  Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.

Authors:  Gege Gui; Christopher S Hourigan
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

Review 2.  Lower risk but high risk.

Authors:  Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Minimally Deviated Lymphohematopoietic Neoplasms: Nomenclature in the Context of Pathobiology.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2021-09-12

Review 4.  Structural variations in cancer and the 3D genome.

Authors:  Frank Dubois; Nikos Sidiropoulos; Joachim Weischenfeldt; Rameen Beroukhim
Journal:  Nat Rev Cancer       Date:  2022-06-28       Impact factor: 69.800

Review 5.  Precision Medicine in Myeloid Malignancies: Hype or Hope?

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Rosalyn I Marar; Prajwal Dhakal; Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-08-16       Impact factor: 4.213

Review 6.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

7.  Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping.

Authors:  Kornelia Neveling; Tuomo Mantere; Susan Vermeulen; Michiel Oorsprong; Ronald van Beek; Ellen Kater-Baats; Marc Pauper; Guillaume van der Zande; Dominique Smeets; Daniel Olde Weghuis; Marian J P L Stevens-Kroef; Alexander Hoischen
Journal:  Am J Hum Genet       Date:  2021-07-07       Impact factor: 11.025

8.  What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.

Authors:  Morten Krogh Herlin; Sara A Yones; Eigil Kjeldsen; Linda Holmfeldt; Henrik Hasle
Journal:  Genes (Basel)       Date:  2021-05-21       Impact factor: 4.096

Review 9.  A Simple Practical Guide to Genomic Diagnostics in a Pediatric Setting.

Authors:  Alan Taylor; Zeinab Alloub; Ahmad Abou Tayoun
Journal:  Genes (Basel)       Date:  2021-05-27       Impact factor: 4.096

Review 10.  Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.

Authors:  Julie Quessada; Wendy Cuccuini; Paul Saultier; Marie Loosveld; Christine J Harrison; Marina Lafage-Pochitaloff
Journal:  Genes (Basel)       Date:  2021-06-17       Impact factor: 4.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.